CIK-CAR.PSMA

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameCIK-CAR.PSMA

Drug Alias Nameanti-PSMA CAR CIK-cell therapy (Formula Pharmaceuticals)anti-PSMA CAR cytokine induced killer cell therapy (Formula Pharmaceuticals)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cellCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesFormula Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFormula Gmbh

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A